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Abstract Neurotransmitter transport systems are major targets
for therapeutic alterations in synaptic function. We have cloned
and sequenced a cDNA encoding the human type 2 glycine
transporter GlyT2 from human brain and spinal cord. An open
reading frame of 2391 nucleotides encodes a 797 amino acid
protein that transports glycine in a Na+/Cl^-dependent manner.
When stably expressed in CHO cells, human GlyT2 displays a
dose-dependent uptake of glycine with an apparent Km of 108
WM. This uptake is not affected by sarcosine at concentrations up
to 1 mM. Radiation hybrid analysis mapped the GlyT2 gene to
D11S1308 (LOD = 8.988) on human chromosome 11p15.1^15.2.
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1. Introduction
The amino acid glycine is thought to have two major roles
in mammalian central neurotransmission. Firstly, glycine acts
as the major inhibitory neurotransmitter in the caudal brain
and spinal cord [1] where its action is mediated by the strych-
nine-sensitive glycine receptor to produce inhibitory post-syn-
aptic potentials [2]. In addition to this inhibitory role, glycine
also modulates excitatory neurotransmission by potentiating
the action of glutamate at N-methyl-D-aspartate (NMDA) re-
ceptors [3,4].
The termination of action of most neurotransmitters is
mediated by rapid re-uptake into the pre-synaptic terminal
or surrounding glial cells [5,6]. The active transport of neuro-
transmitters across the plasma membrane is driven by the
transmembrane Na gradient generated by the plasma mem-
brane Na/K-ATPase [6]. To date, molecular cloning studies
have lead to the identi¢cation of two distinctive gene families
encoding neurotransmitter transporter proteins. These include
the Na/K-dependent (but Cl3-independent) excitatory ami-
no acid transporter family GLAST [7], EAAC-1 [8], GLT1 [9],
and the more recently discovered EAAT4 [10]. The second,
Na/Cl3-dependent family includes transporters for Q-amino-
butyric acid (GABA) [11^15], norepinephrine/epinephrine
[16], dopamine [17^22], serotonin [23,24], proline [25], choline
[26], betaine [27], taurine [28^30], creatine [31] and glycine
[32^37].
High-a⁄nity glycine transporters have so far been shown to
be encoded by two separate genes. GlyT1 [32^34,36,37] occurs
in three separate isoforms (GlyT1a, -1b and -1c) encoded by a
single gene which di¡er only in their amino-terminal region
[32]. GlyT1a and -1b originate from transcription directed
from alternate promoters whereas GlyT1c is a splice variant
of the -1b transcript [38]. GlyT1 is expressed predominantly in
glial cells [38,39] of brain areas such as hippocampus, cortex
and cerebellum, and also in the brain stem and spinal cord
[33,37^41]. Based on its tissue distribution, GlyT1 has been
suggested to co-localise with the NMDA receptor [37] where it
may modulate the concentration of glycine at its co-agonist
binding site [3]. Indeed, a recent study has demonstrated that
GlyT1b has the ability to control the response of the NMDA
receptor when co-expressed in Xenopus oocytes [42].
More recently, a second glycine transporter (GlyT2) was
reported [35] and shown to be encoded by a separate gene.
GlyT2 is distinguishable from GlyT1 in terms of primary
structure (48% amino acid sequence identity), tissue distribu-
tion and pharmacological properties [35]. In contrast to
GlyT1, GlyT2 is predominantly neuronal in nature [39], and
restricted to the spinal cord, brain stem, and to a lesser extent
the cerebellum [39,41,43,44] where it co-localises with strych-
nine binding sites [44]. This correlation with the distribution
of inhibitory, strychnine-sensitive glycine receptors suggests
that GlyT2 is involved in the termination of inhibitory neuro-
transmission at strychnine-sensitive glycinergic synapses.
Abnormalities of neurotransmitter transport can contribute
to neuropathological processes. For example, blockage of
and/or reversal of the glutamate transporters during ischaemia
or anoxia elevates the extracellular concentration of L-gluta-
mate to neurotoxic levels resulting in nerve cell damage
[45,46]. Neurotransmitter transporters are also major targets
for therapeutic and pathological alterations in synaptic func-
tion. This is particularly apparent by the ability of mono-
amine reuptake inhibitors such as tricyclic antidepressants,
amphetamines and cocaine to produce dramatic behavioural
changes [47]. Also, selective GABA reuptake inhibitors (e.g.
tiagabine) are being developed as anticonvulsant and anxio-
lytic agents [48]. Similarly, the development of selective GlyT2
inhibitors could prove to be useful agents for modulating
glycinergic neurotransmission in the caudal brain and spinal
cord.
In this study, we report the isolation of a cDNA from
human brain and spinal cord which is homologous to the
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rat GlyT2 sequence. We show that it encodes a Na- and Cl3-
dependent type 2 glycine transporter with similar pharmacol-
ogy reported for rat GlyT2, and that this transcript is simi-
larly located in spinal cord, brain stem and cerebellum.
2. Materials and methods
2.1. Cloning of human GlyT2
A human GlyT2 probe was prepared by performing PCR on
a human whole brain cDNA library (Vgt11, Clontech) using a
pair of primers (sense: 5P-CAGTGGGGCTGGGTAATGTTTGG-3P
and antisense: 5P-AAAGATGATGGCCCAGAATGGAGA-3P) cor-
responding to conserved regions in the ¢rst and eighth transmembrane
domains of rat GlyT2. Reactions (100 Wl) contained 30 pmol of each
primer, 2.5 U Taq DNA polymerase (Gibco BRL) in 50 mM KCl,
10 mM Tris-HCl, pH 8.3, 2 mM MgCl2, and subjected to 40 cycles
(1 min, 94‡C; 1 min, 60‡C; 1 min 72‡C). This gave rise a product of
expected size (1045 bp) which was puri¢ed using the Geneclean II kit
(Bio 101) and ligated into the TA plasmid pCRII (Invitrogen). All
plasmids were transformed into competent Escherichia coli TOP10FP
cells (Invitrogen) and propagated using standard conditions [49]. The
DNA sequence of the PCR product was con¢rmed by dideoxy se-
quencing using the Pharmacia autoread sequencing kit and ALF au-
tomated DNA sequencer. This product was then used to screen hu-
man whole brain, spinal cord (both Vgt11) and brainstem-medulla
(Vgt10) cDNA libraries (Clontech). Phage (40 000 per 150 mm diam-
eter plate) were transferred to nitrocellulose ¢lters (Costar) as de-
scribed in Sambrook et al. [49]. Filters were prehybridised at 42‡C
for 2 h with 50% formamide, 6USSC (0.9 M NaCl, 0.09 M sodium
citrate, pH 7.0), 5UDenhardt’s (0.1% w/v polyvinylpyrrolidone, 0.1%
w/v Ficoll type 400, 0.1% bovine serum albumin), and 100 Wg/ml
sheared, denatured salmon sperm DNA. Hybridisation was performed
overnight at 42‡C in the same solution containing [32P]dCTP-labeled
probe (DNA probes were prepared using the Pharmacia Ready-To-
Go DNA labeling kit). The ¢lters were washed twice with 2USSC,
0.1% SDS (room temperature), then twice with 0.5USSC, 0.1% SDS
(50‡C) and exposed to Hyper¢lm MP (Amersham).
Positives were picked and puri¢ed by further rounds of screening.
Phage DNA was prepared using the Qiagen lambda maxi kit, with
cDNA inserts being excised by EcoRI digestion and subcloned into
pUC18 for further analysis.
The 5P end of the hGlyT2 cDNA was isolated using the cerebellum
5P-RACE Ready cDNA kit (Clontech). Primary PCR was carried out
using the supplied anchor primer (AP1) together with a gene-speci¢c
primer (antisense: 5P-TGCCCTTGCCCACACTCACGTTCGCAT-
3P). The reaction was carried out with Amplitaq Gold (Perkin-Elmer)
in the manufacturer supplied bu¡er with the addition of 5% DMSO
(94‡C denaturation/activation followed by 30 cycles of 30 s, 94‡C; 30 s
65‡C; 2 min 72‡C). This was followed up by a secondary PCR using
the supplied nested anchor primer (AP2) together with a nested gene-
speci¢c primer (antisense: 5P-CCGCGGGCTACTGAGTTTGCAA-
GACC-3P). Cycling parameters were the same as for the primary
PCR reaction. Four products were obtained of approximately 600
bp, 500 bp, 350 bp and 300 bp and termed RACE clones 1^4 respec-
tively. These were puri¢ed and cloned into pCR2.1 (Invitrogen) and
their identity con¢rmed by dideoxy sequencing.
The full-length hGlyT2 cDNA was constructed using the 5P RACE
PCR products together with the three overlapping cDNA clones
(clones 1, 10 and 11) isolated from the cDNA library screens (Fig.
1A). The 5P end was reconstructed by ligating HindIII/Eco72I frag-
ment from pCR2.1/RACE clone 1 into HindIII/Eco72I digested pUC/
clone 10 DNA. This gave rise to a 5P end clone containing 300 bp of
untranslated 5P leader sequence. The HindIII/NcoI fragment from this
5P end containing clone was ligated together with the NcoI/NaeI frag-
ment from clone 11 and NaeI/EcoRI fragment from clone 1 into
HindIII/EcoRI digested pcDNA3 (Invitrogen) and denoted
pcDNA3/hGlyT2. In this construct, expression of the hGlyT2
cDNA is under control of the CMV IE gene promoter.
2.2. Generation of the genomic/cDNA fusion construct
An earlier attempt at isolating the 5P end of the hGlyT2 sequence
from a genomic clone (isolated from a genomic DNA library in the V
Dash II vector (Stratagene)) revealed a canonical 3P splice acceptor
site at the position where the translational initiation codon was ex-
pected (Fig. 4). In an attempt to increase expression from the
pcDNA3/hGlyT2 construct, a genomic/cDNA fusion was created by
including this intron in the expression construct. The intron was
cloned by PCR using primers directed against exon sequence on either
side of the intron (sense: 5P-CCAGTCTTGTCAATAGCGGGTTT-
CAC-3P ; antisense: 5P-TGCCCTTGCCCACACTCACGTTCGCAT-
3P) using human genomic DNA as a template. PCR was performed
using the Clontech Advantage Genomic PCR kit (95‡C 1 min, then 35
cycles of: 95‡C, 15 s; 68‡C, 12 min). This gave rise to a single frag-
ment of approximately 1800 bp that was puri¢ed and cloned into
pCR2.1 (Invitrogen). Dideoxy sequencing con¢rmed that this frag-
ment contained the intron £anked by exon sequence. The genomic/
cDNA fusion construct was then generated by purifying the EcoRI/
Eco72I fragment from the pCR2.1/genomic sequence and ligating this
with the Eco72I/XhoI fragment from pcDNA3/hGlyT2 into EcoRI/
XhoI-digested pcDNA3.
2.3. Northern blot analysis
The cDNA insert from clone 10 was radiolabeled using the Phar-
macia Ready-To-Go DNA labeling kit. Human multiple tissue North-
ern blots (Clontech) were hybridised for 2 h at 68‡C in ExpressHyb
hybridisation solution (Clontech) and washed in 2USSC, 0.05% SDS
at room temperature, twice for 40 min with 0.1USSC, 0.05% SDS at
50‡C, then exposed to Hyper¢lm MP (Amersham) with one intensify-
ing screen at 380‡C for up to 6 weeks.
2.4. Genomic localisation
The genetic locus of hGlyT2, was determined by PCR assay of the
Genebridge-4 radiation-reduced somatic cell DNA panel consisting of
84 hybrids each containing a previously characterised complement of
human DNA [50] (UK MRC HGMP Resource Centre, Cambridge).
This was performed using primers (sense: 5P-GGCTATTTCCA-
TTCCCCCTTTACCCTTAC-3P and antisense: 5P-TGTTGGCTGG-
CGTTTATTCATTTCCTT-3P) directed against hGlyT2 genomic
sequence (unpublished data) encompassing an intron/exon boundary
with sub-chromosomal mapping of the 334 bp PCR product being
analysed via the Whitehead Institute radiation hybrid map-
per: http://www.genome.wi.mit.edu/ftp/pub/software/rhmapper. Each
PCR reaction was carried out with 100 ng template DNA using Am-
plitaq Gold in the manufacturer-supplied bu¡er and subjected to 30
cycles (30 s, 94‡C; 30 s 56‡C; 40 s, 68‡C). PCR reactions were sub-
sequently electrophoresed on 1% agarose gels and analysed for the
presence of the hGlyT2 product.
2.5. Cell culture and transfection
CHO cells were propagated in culture medium containing Dulbec-
co’s modi¢ed Eagle’s medium (DMEM/Nut mix 1:1 with Gluta-
MAX1, Gibco BRL) supplemented with 10% fetalclone II (Hyclone)
and maintained at 37‡C in a humidi¢ed atmosphere of 5% CO2 in air.
Cells for transfection were trypsinised the day before the experiment
and seeded at 1.5U106 per 10 cm dish.
For transfection, cells were washed twice with OpitMEM (Gibco
BRL) before exposure to transfection medium for 5 h. Transfection
medium consisted of 16 Wg of DNA and 100 Wl LipofectAMINE
(Gibco BRL). After 5 h, 5 ml of growth medium plus 20% FBS
was added, the cells incubated overnight, and the medium changed
again. Stably transfected cells were selected for 1 week in growth
medium containing 2 mg/ml Geneticin (Gibco BRL), and the remain-
ing cells transferred to cloning plates in growth medium containing
1 mg/ml Geneticin. Individual clones were picked for further analysis
and positives passaged routinely in growth medium containing
0.5 mg/ml Geneticin. Cells were seeded in either 24 well plates
(200 000 cells/well) or 96 well plates (30 000 cells/well) 24 h before
assaying.
2.6. Glycine uptake assay
To measure glycine transport, cells were washed twice with Hanks’
balanced salts solution (HBSS). The plates were then equilibrated to
37‡C with HBSS for 5 min (400 Wl in 24 well plates; 200 Wl in 96 well
plates). For uptake inhibition studies, glycine and sarcosine were in-
cluded at this stage. In 24 well plates, 100 Wl of [3H]glycine (150 WM,
248 Bq/nmol, NEN) was added to each well with a further 100 Wl
aliquot taken for scintillation counting to determine total activity
added. Incubation was continued for 5 min and uptake terminated
by washing the cells three times with ice-cold HBSS. After removal of
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excess liquid, 250 Wl of 1% sodium dodecyl sulphate was added to
each well and the plates left for 1 h. A 150 Wl aliquot was removed for
scintillation counting and placed in a 6 ml scintillation vial with 2 ml
Ultima Gold scintillation cocktail (Canberra Packard). For 96 well
plates, 50 Wl of [3H]glycine (50 WM, 248 Bq/nmol) was added to each
well with a further 50 Wl taken for scintillation counting to determine
total activity added. Incubation was continued for 20 min and uptake
terminated by washing the cells with three aliquots of ice-cold HBSS.
After removal of excess liquid, 200 Wl of Microscint 20 cocktail (Can-
berra Packard) was added. The plates were then sealed with Topseal
¢lm and shaken to ensure samples were homogenous before scintilla-
tion counting in a plate counter (1450 MicroBeta Trilux, Wallac).
Data were analysed using the GraphPad Prism analysis package
and the curve ¢tting option sigmoid dose response (variable slope)
to produce pIC50 (the negative logarithm of the concentration of
test compound causing 50% inhibition of uptake) values where appro-
priate.
3. Results
3.1. Cloning and analysis of hGlyT2 cDNA
In order to clone the human type 2 glycine transporter,
PCR was performed on a human whole-brain cDNA library
using oligonucleotides based on the rat GlyT2 sequence and
directed against regions of high homology (transmembrane
domains 1 and 8 respectively) in the Na/Cl3-dependent
transporter family. This produced a fragment of expected
size (1045 bp) which, when cloned and sequenced, was found
to be highly homologous (91%) to the corresponding rat
GlyT2 sequence. The polypeptide encoded by this fragment
is 98.8% homologous to the corresponding rat GlyT2 se-
quence with all four amino acid residue substitutions being
conservative. These di¡erences are consistent with the PCR
product being the likely human homologue of the rat GlyT2
sequence. This PCR product was then used to screen cDNA
libraries derived from human spinal cord and brain stem (me-
dulla), areas which, in the rat, have been demonstrated to be
rich in GlyT2 mRNA [39,41,43,44]. This gave rise to three
overlapping positive cDNA clones (Fig. 1A). The ¢rst (clone
1), isolated from the medulla library (from a total of 2.4
million clones screened), was 1008 bp long and included the
3P end of the human GlyT2 reading frame. Screening a similar
number of clones from the spinal cord library gave rise to
another two clones (clone 10, 968 bp and clone 11, 1490
bp). Analysis of these clones indicated that clone 10, which
extended furthest 5P of the three clones, terminated 26 bp
short of the expected translational initiation codon when com-
pared to the rat GlyT2 sequence. The remaining 5P sequence
of the hGlyT2 cDNA was ¢nally isolated using 5P RACE
PCR. This generated four products with the longest including
300 bp of 5P untranslated leader sequence. The full-length
hGlyT2 sequence was generated using the overlapping
RACE and cDNA clones as described in Section 2.
Analysis of the full-length cDNA (Fig. 1B) revealed a 2391
bp reading frame encoding a 797 amino acid polypeptide with
a calculated molecular mass of 87 370 Da. This is 88% homol-
ogous with the rat GlyT2 sequence at the DNA level and 94%
at the amino acid level (Fig. 2) which is consistent with this
cDNA encoding the human homologue of the rat GlyT2 se-
quence. Interestingly, most (42 from 47) of the di¡erences at
the amino acid level occur within the extended hydrophilic
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Fig. 2. Alignment of the amino acid sequences of human GlyT1b, GlyT2 and rat GlyT2. The deduced amino acid sequences of human GlyT1b,
GlyT2 and rat GlyT2 were aligned using a DNAman program. Conserved amino acid residues are indicated with a star, while conservative
changes are marked with a dot. Putative transmembrane domains are marked by solid lines above the sequence.
Fig. 1. A: Reconstruction of the full-length human GlyT-2 cDNA. The full-length cDNA was constructed using the three overlapping cDNA
clones (clones 1, 10 and 11) isolated from the human brain stem (medulla) and spinal cord cDNA libraries, together with the RACE PCR
clone containing the 5P end. The relative positions of these clones are indicated in the ¢gure together with the restriction enzyme sites used to
fuse the fragments together as described in Section 2. The positions of the translational initiation and stop codons are also shown, and the bot-
tom line represents a scale bar marked o¡ in kb. B: Nucleotide and deduced amino acid sequence of the cDNA encoding the human glycine
transporter GlyT-2. The cDNA was cloned and sequenced as described in Section 2. Putative N-linked glycosylation sites are indicated by a
star and protein kinase C phosphorylation sites are underlined in bold.
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amino-terminal domain. The deduced protein contains ¢ve
potential N-linked glycosylation sites; four in the large extra-
cellular loop between the putative third and fourth transmem-
brane domains (Asn-343, 353, 358, 364) and one (Asn-712)
between the 11th and 12th transmembrane domains. All are
conserved in the rat sequence. There are also six consensus
sites for protein kinase C-dependent phosphorylation: Ser-79,
84, 124 and 195 in the long amino-terminal domain (84 and
195 are conserved in the rat sequence); Ser-417 between trans-
membrane domains 4 and 5 where similar sites are found in
several other members of this transporter family [32,51], and a
threonine at position 600 between transmembrane domains 8
and 9.
3.2. Northern blot analysis
To determine the tissue distribution of the mRNA encoding
hGlyT2, Northern analysis was performed with blots contain-
ing mRNA isolated from di¡erent parts of the human CNS
using clone 10 as a hGlyT2-speci¢c cDNA probe. This probe
hybridised weakly to a single band of approximately 9.5 kb in
medulla, and to a lesser extent in spinal cord and cerebellum
(Fig. 3). No signal was observed in any other brain area,
including whole brain mRNA. This is consistent with the
known tissue distribution of GlyT2 mRNA in the rat nervous
system [39,41,43,44].
3.3. Genomic localisation
PCR analysis of the Genebridge-4 radiation-reduced so-
matic cell DNA panel [50] for a hGlyT2 speci¢c product
(data not shown) indicated that the GlyT2 gene maps to locus
D11S1308 on chromosome 11 (LOD = 8.988). This corre-
sponds to the cytogenetic band 15.1^15.2 on the short arm
of chromosome 11 (11p15.1^15.2).
3.4. Stable expression of hGlyT2 in CHO cells
In order to determine the substrate speci¢city and kinetics
of this transporter, the putative hGlyT2 cDNA was trans-
fected into CHO cells. Initial studies (data not shown) dem-
onstrated that this cDNA exhibited very low levels of expres-
sion, however, a genomic/cDNA fusion construct containing a
single endogenous intron found at the 5P end of the human
GlyT2 gene (Fig. 4; generated as described in Section 2) ex-
hibited somewhat higher levels. Stable cell lines were then
established using this construct with one, clone #91, being
employed in all subsequent analysis.
To determine the speci¢city of the transporter, the CHO/
hGlyT2 cell line was assayed for its ability to accumulate a
variety of potential substrates. As observed in Fig. 5A, this
cell line accumulated up to 15-fold more [3H]glycine than the
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Fig. 5. A: Uptake of a range of 3H-labeled substrates (5 nM) in
CHO/hGlyT-2 clone 91 and in the untransfected parental cell line
(CHO(3)). B: Ionic dependence of glycine uptake in hGlyT2 clone
and in the untransfected parental cell line (CHO(3)). Data are ex-
pressed as % of the control conditions ([Na] = 142 mM, [Cl3] = 145
mM) for CHO (hGlyT-2). Error bars indicate standard deviation
(n = 3).
Fig. 4. Generation of the genomic/cDNA fusion construct. The
cDNA sequence is shown on the top line with the translational ini-
tiation codon highlighted in bold. The position of the single endoge-
nous intron cloned and incorporated into the cDNA sequence as
described in Section 2 is indicated by the arrow. The lower line
shows the genomic sequence with the intron sequence in lower case.
The GT/AG dinucleotides typically found at 5P and 3P splice junc-
tions respectively are underlined.
Fig. 3. Localisation of hGlyT2 in the nervous system. Northern hy-
bridisation was performed as described in Section 2. The size of
RNA standards is indicated in kb. A single speci¢c band of approx-
imately 9.5 kb is indicated in medulla, cerebellum and less clearly in
spinal cord. No signal is observed in any other brain area.
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parental untransfected CHO cell line. Furthermore, there was
no signi¢cant di¡erence in uptake of a number of other sub-
strates including radiolabeled proline, GABA, choline, leu-
cine, glutamate, dopamine, norepinephrine and serotonin.
Glycine transport exhibited by this cell line was also demon-
strated to be Na- and Cl3dependent by the substitution of
these ions by Li and acetate (Fig. 5B).
To determine the kinetics of the transporter, the CHO/
hGlyT2 cell line was incubated with varying concentrations
of [3H]glycine, and the speci¢c accumulation of radioactivity
determined. A representative experiment illustrated in Fig. 6
demonstrates that GlyT2 confers saturable uptake with a Mi-
chaelis constant (Km) of 108 WM. This ¢gure was calculated
by subtracting the low-a⁄nity glycine uptake endogenous to
CHO cells from the total uptake exhibited by the CHO/
hGlyT2 cell line (Fig. 6A), to yield the apparent high-a⁄nity
component expressed by GlyT2 (Fig. 6B). Glycine inhibited
the accumulation of [3H]glycine with a pIC50 value of
4, whereas sarcosine (N-methylglycine), which has been shown
to inhibit GlyT1 in a dose-dependent manner [35,37], had no
e¡ect on glycine uptake by hGlyT2 at concentrations up to
1 mM (Fig. 7). This observation is similar to that reported for
the cloned rat GlyT2 cDNA [35], and accordingly, we con-
clude that our cDNA encodes the human type 2 glycine trans-
porter.
4. Discussion
In this study, we report the isolation of a cDNA encoding a
high-a⁄nity Na/Cl3-dependent type 2 glycine transporter
from human brain and spinal cord. The protein encoded by
this cDNA shares many of the features common to members
of the Na/Cl3-dependent transporter family and is highly
homologous to the rat GlyT2 sequence. Expression of this
cDNA in stably transfected CHO cells resulted in high a⁄nity
glycine uptake with a Km of 108 WM. This is higher than that
reported for rat GlyT2 and probably re£ects the nature of the
expression systems used (oocytes for rat vs eukaryotic cell line
(CHO) for human). Indeed, this is reminiscent of the discrep-
ancies noted for GlyT1 with Kms of 94 WM (CV-1 cells) [33],
123 WM (COS-7 cells) [37] compared 32 WM [34] and 25 WM
[36] when expressed in oocytes. Also, the lack of inhibition by
sarcosine that distinguishes GlyT1 from GlyT2 leads us to the
conclusion that our cDNA encodes the human homologue of
the rat GlyT2 sequence.
Glycine is transported by three classically de¢ned systems
distinguishable by substrate a⁄nities and ionic dependence
[52,53]. The type 2 glycine transporters reported by ourselves
and Lui et al. [35], together with GlyT1, most likely constitute
at least part of system Gly that is most speci¢c for glycine and
its N-methyl derivative, sarcosine [54]. The high selectivity of
these transporters for glycine clearly distinguishes them from
the other two classically de¢ned amino acid transporter sys-
tems, system A and system ASC, which possess much broader
speci¢city. Indeed, molecular cloning studies have demon-
strated that at least one component of system ASC is encoded
by a novel transporter, ASCT-1 [55] whose structure is very
similar to that of the glutamate transporter gene family. An-
other, SAAT-1 [56], encodes a neutral amino acid transporter
similar to Na/glucose cotransporters with speci¢city charac-
teristics of system A.
Chromosomal localisation mapped the GlyT2 gene on hu-
man chromosome 11p15.1^15.2, however, this does not corre-
late to any likely known disease locus. Localisation of the
hGlyT2 mRNA by Northern analysis revealed a 9.5 kb tran-
script restricted to brain stem, spinal cord and cerebellum
which correlates well with a number of more detailed studies
of GlyT2 mRNA in rat [33,34,37,38,41,44]. A number of stud-
ies have examined in detail the distribution of GlyT1 and
GlyT2 by in situ hybridisation [33,34,37,38,41,44], and more
recently by immunocytochemistry with antibodies raised
against peptides corresponding to parts of the amino acid
sequences of these molecules [39,57]. These studies have dem-
onstrated that GlyT2 is predominantly neuronal with the ex-
ception of the cerebellum where it is also found in glial ele-
ments of the molecular layer [39]. Its localisation in brain stem
and spinal cord correlates well with the distribution of the
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Fig. 7. Inhibition of [3H]glycine uptake in CHO/hGlyT-2 clone 91.
Data obtained in the untransfected cell line (CHO) has been sub-
tracted from the corresponding values for clone 91 to produce the
above curves. Data taken from a representative experiment (n = 3).
Fig. 6. Uptake of glycine during a 20 min period as a function of
increasing substrate concentration. A: Data for clone 91 (b) and
untransfected parental cell line (a). B: Di¡erence between trans-
fected and untransfected cell lines (F).
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strychnine-sensitive glycine receptor [2], and indeed, there is a
high level of correspondence between GlyT2 levels and strych-
nine binding sites in the CNS [43]. Ultrastructural analysis of
immunocytochemical staining using antisera directed against
GlyT2 has indicated the presence of the protein in axons and
axonal boutons enriched with glycine-like immunoreactivity
[57]. Conversely, with the exception of the retina, areas devoid
of strychnine-sensitive glycine receptors are also low in GlyT2.
This evidence strongly suggests that GlyT2 is responsible for
the termination of neurotransmission at strychnine-sensitive
glycinergic synapses. While GlyT1 is also abundantly ex-
pressed in brain stem and spinal cord, it is also found in
more rostral regions such as hypothalamus, thalamus and
hippocampus [37,39]. Its presence in areas devoid of inhibi-
tory glycinergic neurons and rich in NMDA receptors has
lead to speculation that GlyT1 has a role in regulation of
glycine levels in NMDA receptor-mediated neurotransmis-
sion, however, this has yet to be established unambiguously.
Indeed, there is some speculation that GlyT1 may have a role
in the regulation of glycine levels at the strychnine- (and non-
strychnine-) sensitive inhibitory glycine receptors [39,41]. The
relationship between GlyT1, GlyT2 and the NMDA/strych-
nine-sensitive glycine receptors, especially in areas rich in all
four molecules such as spinal cord, is particularly intriguing
and may only be resolved following the development of selec-
tive inhibitors of these transporters.
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